Merck Group
Pharmaceuticals
Germany
EU Taxonomy summary
29.48% of Merck Group's revenues are EU Taxonomy eligible, with 0.01% also being Taxonomy aligned. 4.8% of Merck Group's capital expenditures are EU Taxonomy eligible, with 0.07% also being Taxonomy aligned. Additionally, 1.35% of Merck Group's operating expenses are EU Taxonomy eligible, with 0.02% also being Taxonomy aligned.
Merck Group's revenues breakdown
Merck Group's capital expenditures breakdown
Merck Group's operating expenses breakdown
EU Taxonomy full disclosure
Revenues
| FY2024 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.5 = Manufacture of energy efficiency equipment for buildings |
CCM 3.5 | 1 | 0.01% | Y | N/EL | N/EL | N/EL | N/EL | N/EL | Y | Y | Y | Y | Y | Y | 0.03% | E | |||
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
1 | 0.01% | 100% | 0% | 0% | 0% | 0% | 0% | 0.03% | |||||||||||
Of which enabling |
1 | 0.01% | 100% | 0% | 0% | 0% | 0% | 0% | 0.03% | E | ||||||||||
Of which transitional |
0 | 0% | 0% | 0% | T | |||||||||||||||
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances |
PPC 1.1 | 125 | 0.59% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 0.47% | ||||||||||
1.2 = Manufacture of medicinal products |
PPC 1.2 | 6,011 | 28.41% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 27.52% | ||||||||||
1.2 = Manufacture of electrical and electronic equipment |
CE 1.2 | 99 | 0.47% | N/EL | N/EL | N/EL | N/EL | EL | N/EL | 0.47% | ||||||||||
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
6,236 | 29.48% | 0% | 0% | 0% | 98.406% | 1.594% | 0% | 28.46% | |||||||||||
A. Turnover of Taxonomy eligible activities (A.1+A.2) |
6,237 | 29.48% | 0.034% | 0% | 0% | 98.406% | 1.594% | 0% | ||||||||||||
Turnover of Taxonomy-non-eligible activities |
14,919 | 70.52% | ||||||||||||||||||
Total (A+B) |
21,156 | 100% |
Show more...Show less...
Capital expenditures
| FY2024 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.5 = Manufacture of energy efficiency equipment for buildings |
CCM 3.5 | 1 | 0.02% | Y | N/EL | N/EL | N/EL | N/EL | N/EL | Y | Y | Y | Y | Y | Y | 0.06% | E | |||
4.1 = Electricity generation using solar photovoltaic technology |
CCM 4.1 | 1 | 0.04% | Y | N/EL | N/EL | N/EL | N/EL | N/EL | Y | Y | Y | Y | Y | Y | 0.17% | E | |||
7.2 = Renovation of existing buildings |
CCM 7.2 | 0 | 0% | Y | N/EL | N/EL | N/EL | N | N/EL | Y | Y | Y | Y | Y | Y | 0.43% | T | |||
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
2 | 0.07% | 100% | 0% | 0% | 0% | 0% | 0% | 0.66% | |||||||||||
Of which enabling |
2 | 0.07% | 100% | 0% | 0% | 0% | 0% | 0% | E | |||||||||||
Of which transitional |
0 | 0% | 0% | T | ||||||||||||||||
6.5 = Transport by motorbikes, passenger cars and light commercial vehicles |
CCM 6.5 | 28 | 1.22% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | 1.35% | ||||||||||
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances |
PPC 1.1 | 1 | 0.05% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 0.04% | ||||||||||
1.2 = Manufacture of medicinal products |
PPC 1.2 | 81 | 3.47% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 4.27% | ||||||||||
CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
111 | 4.73% | 25.793% | 0% | 0% | 74.419% | 0% | 0% | 5.67% | |||||||||||
A. CapEx of Taxonomy eligible activities (A.1+A.2) |
112 | 4.8% | 26.667% | 0% | 0% | 73.333% | 0% | 0% | ||||||||||||
CapEx of Taxonomy-non-eligible activities |
2,229 | 95.2% | ||||||||||||||||||
Total (A+B) |
2,341 | 100% |
Show more...Show less...
Operating expenses
| FY2024 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.5 = Manufacture of energy efficiency equipment for buildings |
CCM 3.5 | 1 | 0.02% | Y | N/EL | N/EL | N/EL | N/EL | N/EL | Y | Y | Y | Y | Y | Y | 0.02% | E | |||
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
1 | 0.02% | 100% | 0% | 0% | 0% | 0% | 0% | 0.02% | |||||||||||
Of which enabling |
1 | 0.02% | 100% | 0% | 0% | 0% | 0% | 0% | 0.02% | E | ||||||||||
Of which transitional |
0 | 0% | 0% | 0% | T | |||||||||||||||
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances |
PPC 1.1 | 1 | 0.05% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 0.11% | ||||||||||
1.2 = Manufacture of medicinal products |
PPC 1.2 | 32 | 1.24% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | 1.73% | ||||||||||
1.2 = Manufacture of electrical and electronic equipment |
CE 1.2 | 1 | 0.04% | N/EL | N/EL | N/EL | N/EL | EL | N/EL | 0.16% | ||||||||||
OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
34 | 1.33% | 0% | 0% | 0% | 96.992% | 3.008% | 0% | 1.99% | |||||||||||
A. OpEx of Taxonomy eligible activities (A.1+A.2) |
35 | 1.35% | 1.481% | 0% | 0% | 95.556% | 2.963% | 0% | ||||||||||||
OpEx of Taxonomy-non-eligible activities |
2,556 | 98.65% | ||||||||||||||||||
Total (A+B) |
2,591 | 100% |
Show more...Show less...